Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension

DOI Web Site PubMed 7 Citations 54 References
  • Yanagisawa Ryoji
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Kataoka Masaharu
    Second Department of Internal Medicine, Kyorin University School of Medicine Department of Cardiology, Keio University School of Medicine
  • Taguchi Hiroki
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Kawakami Takashi
    Department of Cardiology, Keio University School of Medicine
  • Tamura Yuichi
    Department of Cardiology, Keio University School of Medicine
  • Fukuda Keiichi
    Department of Cardiology, Keio University School of Medicine
  • Yoshino Hideaki
    Second Department of Internal Medicine, Kyorin University School of Medicine
  • Satoh Toru
    Second Department of Internal Medicine, Kyorin University School of Medicine

Search this article

Abstract

Background: Sildenafil has been demonstrated as effective for the treatment of pulmonary arterial hypertension (PAH). The purpose of this study was to investigate the occurrence of clinical events after sildenafil monotreatment as a first-line therapy in patients with PAH over a long-term observation period. Methods and Results: Sildenafil was administered as a first-line drug to 46 patients with PAH (including 24 patients with idiopathic PAH) during 2003-2010. We investigated subsequent clinical events such as the addition of epoprostenol, hospitalization for right-side heart failure, and death. All the hemodynamic parameters and the 6-min walk distance improved significantly in the enrolled patients as a whole receiving sildenafil treatment; 15 (33%) of the 46 patients required the addition of epoprostenol during follow-up. Kaplan-Meier analysis demonstrated that more than 60% of the patients receiving first-line sildenafil treatment did not require the addition of epoprostenol for a 5-year period. Furthermore, the 5-year survival rate after first-line sildenafil treatment was 81%. Finally, more than 75% of the enrolled patients did not reach the composite endpoint of hospitalization for right-side heart failure and death for a 5-year period. Conclusions: This study describes the long-term outcome of patients with PAH receiving sildenafil monotreatment as a first-line therapy and suggests that it is a promising therapeutic strategy. (Circ J 2012; 76: 1245-1252)<br>

Journal

  • Circulation Journal

    Circulation Journal 76 (5), 1245-1252, 2012

    The Japanese Circulation Society

Citations (7)*help

See more

References(54)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top